ArticleBlood advances2017
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05199311 (A Phase I/II Study of Carfilzomib, Iberdomide), which is not on this map. Cited by 29 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma
Who cites it
29 citing papers in PubMed, 5 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis.BMJ open · 2023Pooled it
- Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.International journal of molecular sciences · 2023Pooled it
- Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.Haematologica · 2023Pooled it
- Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.Advances in therapy · 2022Pooled it
- Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020Pooled it
- The past, present, and future of myeloma staging and risk prognostication.The oncologist · 2025Review
- Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group.BMC cancer · 2025Article
- Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.Hematological oncology · 2022Article
- Article
- Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.CEN case reports · 2022Article
- Monocyte or white blood cell counts and βTherapeutic advances in hematology · 2022Article
- Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities.Cancers · 2021Review
- Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.Frontiers in oncology · 2021Article
- Animal Models of Multiple Myeloma Bone Disease.Frontiers in genetics · 2021Review
- Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen.International journal of hematology · 2020Article
- Review
- Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.Journal of hematology & oncology · 2019Article
- Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.Clinical pharmacokinetics · 2019Review
- Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.International journal of molecular sciences · 2018Review
- Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients.Hematology. American Society of Hematology. Education Program · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite major therapeutic advancements, multiple myeloma (MM) is still incurable and relapsed/refractory multiple myeloma (RRMM) remains a challenge; the rational choice of the most appropriate regimen in this setting is currently undefined. We performed a systematic review and 2 standard pairwise meta-analyses to evaluate the efficacy of regimens that have been directly compared with bortezomib or immunomodulatory imide drugs (IMiDs) in head-to-head clinical trials and a network meta-analysis (NMA) to determine the relevance of each regimen on the basis of all the available direct and indirect evidence. Sixteen trials were included in the pairwise meta-analyses, and 18 trials were included in the NMA. Pairwise meta-analyses showed that a 3-drug regimen (bortezomib- or IMiD-based) was superior to a 2-drug regimen in progression-free-survival (PFS) and overall response rate (ORR). NMA showed that an IMiD backbone associated with anti-MM monoclonal antibodies (mAbs) (preferably) or proteasome inhibitors had the highest probability of being the most effective regimen with the lowest toxicity. The combination of daratumumab, lenalidomide, and dexamethasone ranked as the first regimen in terms of activity, efficacy, and tolerability according to the average value between surface under the cumulative ranking curve of PFS, overall survival, ORR, complete response rate, and safety. This is the first NMA comparing all currently available regimens evaluated in published randomized trials for the treatment of RRMM, but our results need to be interpreted taking into account differences in their patient populations. Our analysis suggests that IMiDs plus new anti-MM mAb-containing regimens are the most active therapeutic option in RRMM.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.